It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The evolution and progression of multiple myeloma and its precursors over time is poorly understood. Here, we investigate the landscape and timing of mutational processes shaping multiple myeloma evolution in a large cohort of 89 whole genomes and 973 exomes. We identify eight processes, including a mutational signature caused by exposure to melphalan. Reconstructing the chronological activity of each mutational signature, we estimate that the initial transformation of a germinal center B-cell usually occurred during the first 2nd-3rd decades of life. We define four main patterns of activation-induced deaminase (AID) and apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) mutagenesis over time, including a subset of patients with evidence of prolonged AID activity during the pre-malignant phase, indicating antigen-responsiveness and germinal center reentry. Our findings provide a framework to study the etiology of multiple myeloma and explore strategies for prevention and early detection.
The initial mutational processes and how these lead to progression in multiple myeloma (MM) are unclear. Here, the authors identify mutational signatures that occur over time in a large cohort of MM patients and suggest features that may help in early diagnosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
2 Wellcome Sanger Institute, The Cancer, Ageing and Somatic Mutation Programme, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382)
3 University of Milan, Department of Oncology and Hemato-Oncology, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822); Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology and Hematology, Milan, Italy (GRID:grid.417893.0) (ISNI:0000 0001 0807 2568)
4 University of California, Division of Hematology/Oncology, Department of Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
5 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Patologia Molecular de Neoplàsies Limfoides, Barcelona, Spain (GRID:grid.10403.36); Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
6 University of Milan, Department of Oncology and Hemato-Oncology, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822); University of Turin, Department of Molecular Biotechnologies and Health Sciences, Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580)
7 Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology and Hematology, Milan, Italy (GRID:grid.417893.0) (ISNI:0000 0001 0807 2568)
8 Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
9 CRCINA, SIRIC ILIAD, University Hospital of Nantes, Nantes, France (GRID:grid.277151.7) (ISNI:0000 0004 0472 0371)
10 Center for Computational Oncology, Memorial Sloan Kettering Cancer Center, Computational Oncology Service, Department of Epidemiology & Biostatistics, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
11 University of California, La Jolla, Department of Cellular and Molecular Medicine and Department of Bioengineering and Moores Cancer Center, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
12 Universitat de Barcelona, Unitat Hematopatologia, Hospital Clínic of Barcelona, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); Universidad de Oviedo, Departamento de Bioquimica y Biologia Molecular, Instituto Universitario de Oncologia (IUOPA), Oviedo, Spain (GRID:grid.10863.3c) (ISNI:0000 0001 2164 6351)
13 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Patologia Molecular de Neoplàsies Limfoides, Barcelona, Spain (GRID:grid.10403.36); Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427); Universitat de Barcelona, Unitat Hematopatologia, Hospital Clínic of Barcelona, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)
14 Ulm University and Ulm University Medical Center, Institute of Human Genetics, Ulm, Germany (GRID:grid.410712.1)
15 IUC-Oncopole, and CRCT INSERM U1037, Toulouse, France (GRID:grid.410712.1)
16 Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Veterans Administration Boston Healthcare System, West Roxbury, USA (GRID:grid.410370.1) (ISNI:0000 0004 4657 1992)
17 Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952); Wellcome Sanger Institute, The Cancer, Ageing and Somatic Mutation Programme, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382)